| Abstrakt: |
Objective: The determination of a single urinary biochemical marker of bone turnover, N-telopeptide, has been proposed as a screening test to classify bone mineral density (BMD) of the hip as normal, osteopenic, or osteoporotic bone. The purpose of this study was to determine the value of a different urinary biochemical marker of bone turnover, deoxypyridinoline (Dpd), as a cost-effective method to discriminate osteopenia or osteoporosis of the hip.Methods: A urinary assay of Dpd and a BMD were prospectively performed in estrogen-depleted women (n = 120) who had never received remedial bone treatment.Results: The urinary Dpd showed a negative correlation to all regions of the hip, but it did not reliably distinguish normal, osteopenic, or osteoporotic BMD. In fact, the body-mass index showed a stronger correlation to the hip BMD. Moreover, the Dpd excretion would have missed 53% of clinically relevant osteopenia or osteoporosis cases.Conclusions: A single measurement of the urinary Dpd cannot be used as a screening test or as a replacement for a BMD study to determine hip osteopenia or osteoporosis. [ABSTRACT FROM AUTHOR] |
